Home › Seattle Genetics and Takeda's cancer drug meets main trial goal
 

Keywords :   


Seattle Genetics and Takeda's cancer drug meets main trial goal

2014-09-29 19:14:26| Biotech - Topix.net

Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Patients who received the drug, Adcetris, immediately after a stem cell transplant, lived significantly longer without the disease progressing than those who were given a placebo, the companies said in a joint statement.

Tags: main trial goal drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Atlantic Tropical Weather Outlook
29.06Eastern North Pacific Tropical Weather Outlook
28.06What we learned from IT expert at Post Office inquiry
28.06M&S to launch clothing repairs service
28.06Tropical Depression Two Graphics
28.06Tropical Depression Two Public Advisory Number 1
28.06Summary for Tropical Depression Two (AT2/AL022024)
28.06Tropical Depression Two Forecast Advisory Number 1
More »